Negotiations and Formularies PBMs incentivize higher rebates through formulary design
Lpez-Gmez JJ, Prez-Castrilln JL, Garca de Santos I, Prez-Alonso M, Izaola-Jauregui O, Primo-Martn D, et al
With growing usage comes reshaped consumer spending patterns
From identity and purpose to longevity, equity, financial health, sex and relationships, and the gaps in research, care, and policy, no topic will be off-limits
Rinne ST, Feemster LC, Collins BF, et al
No, GLP-1 receptor agonists are not licensed or recommended for treating high cortisol